All In Biotech

Drug Trial Radar · NCT02310672

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Jun 1, 2015

Primary completion

Sep 10, 2019

Study completion Sep 10, 2019

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year. Patients undergo right heart catheterization (RHC) at baseline and Week 26. They also undergo cardiac magnetic resonance imaging (MRI) at baseline, Week 26 and Week 52. Safety is monitored throughout the study. The study has three stub-studies. Each patient can participate in no sub-study or in one sub-study. The sub-studies are: (1) metabolism sub-study (with PET-MR scans); (2) biopsy sub-study (biopsies taken during the RHC); (3) Echo sub-study.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • MacitentanDrug

    All patients take open-label macitentan 10mg o.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26Time frame: Baseline and Week 26
  2. Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR)Time frame: Baseline and Week 26

Locations

41 sites in 12 countries. Site status is shown where the registry gives one.

  • Massachussetts General Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Rudgers New Jersey Medical School

    New Brunswick, New Jersey

  • Cornell University

    New York, New York

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical

    Dallas, Texas

  • St. Luke's Medical Center

    Milwaukee, Wisconsin

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Hopital Gabriel Montpied

    Clermont-Ferrand, France

  • Hôpital Michallon

    La Tronche, France

  • "CHRU de Lille - Hôpital Albert Calmette "

    Lille, France

  • Hopital de Brabois

    Nancy, France

  • Hôpital Laennec

    Nantes, France

  • Hôpital Pasteur

    Nice, France

  • Hôpital Européen Georges-Pompidou

    Paris, France

  • Medizinische Klinik und Poliklinik II Universitätsklinik Bonn

    Bonn, Germany

  • Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin

    Cologne, Germany

  • Thoraxklinik am Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase

    Mainz, Germany

  • Grantham Hospital, Cardiac Medical Unit

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • United Christian Hospital

    Hong Kong, Hong Kong

  • Pulmonology institute, Soroka Medical Center

    Beersheba, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Policlinico Sant'Orsola-Malpighi

    Bologna, Italy

  • Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti

    Pavia, Italy

  • Hospital Pulau Pinang

    George Town, Malaysia

  • Institut Jantung Negara (National Heart Institute)

    Kuala Lumpur, Malaysia

  • VU University Medical Center (VUMC)

    Amsterdam, Netherlands

  • Maastricht UMC+

    Maastricht, Netherlands

  • St. Antonius Ziekenhuis

    Nieuwegein, Netherlands

  • Radboud UMC

    Nijmegen, Netherlands

  • Erasmus University medical Center

    Rotterdam, Netherlands

  • Russian Cardiology Scientific and Production Complex

    Moscow, Russia

  • Almazov Federal North-West Medical Research Centre of Department of Health

    Saint Petersburg, Russia

  • National University Hospital - The Heart Institute - Cardiac Department

    Singapore, Singapore

  • National Heart Centre (NHC) Singapore

    Singapore, Singapore

  • Golden Jubilee National Hospital

    Glasgow, United Kingdom

  • The Royal Free Hospital

    London, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.